← Back to screener

Celldex Therapeutics, Inc. CLDX

Rank #2340 · Nasdaq · $2.4B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
23.5
P/E
-16.7
P/B
7.24
ROE
-43.4%
Op. Margin
-2245.3%
Debt Ratio
14%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -16.7x, P/B 7.24x. Ranks in the top 78% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -43.4%. Ranks in the top 92% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 14%. Ranks in the top 11% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 192.0% year over year. Ranks in the top 2% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B$-0.0B–$0.0B-242.8191
2012$0.0B$-0.0B–$0.1B-13.840
2013$0.0B$-0.0B–$0.1B-468.440
2014$0.0B$-0.1B–$0.1B-518.540
2015$0.0B$-0.1B–$0.1B-1981.138
2016$0.0B$-0.1B–$0.3B-3414.115
2017$0.0B$-0.1B–$0.2B-2363.956
2018$0.0B$-0.1B–$0.3B-1958.727
2019$0.0B$-0.1B–$0.3B-953.712
2020$0.0B$-0.2B–$0.2B-1640.112
2021$0.0B$-0.1B–$0.1B-1540.221
2022$0.0B$-0.1B–$0.1B-854.127
2023$0.0B$-0.1B–$0.2B-1531.813
2024$0.0B$-0.1B–$0.4B-4889.09
2025$0.0B$-0.2B$-0.1B$0.3B-2245.314

← See the full screener